Loading organizations...
Entia is a technology company.
Entia develops medical devices and an accompanying platform for remote patient monitoring, specifically focused on enabling at-home blood tests. Their core offering allows for decentralized diagnostics, providing patients with the capability to monitor key health markers outside of traditional clinical settings. This technology primarily supports effective cancer care by facilitating the prediction and prevention of treatment side effects.
The company was founded in the mid-2010s by Toby Basey-Fisher and Millie Clive-Smith. Their foundational insight stemmed from the critical need to enable sophisticated blood testing in patients' homes or remote locations, thereby democratizing access to crucial diagnostic information. This vision addresses significant logistical challenges in traditional healthcare delivery.
Entia's solutions cater to patients managing cancer and other chronic health conditions, offering them greater autonomy and convenience in their health management. The company's long-term vision is to transform the experience of living with these conditions by significantly improving access to blood tests, empowering individuals with self-testing capabilities, and making diagnostic monitoring universally accessible.
Entia has raised $45.0M across 3 funding rounds.
Entia has raised $45.0M in total across 3 funding rounds.
Entia is a London‑based medtech company that builds at‑home blood testing and remote monitoring solutions for oncology care, most notably the Entia Liberty full blood count analyser and associated virtual‑oncology services designed to reduce hospital visits and detect treatment toxicity earlier[3][1]. Entia’s product suite targets cancer patients, clinicians and life‑science partners by enabling haematological monitoring at home and feeding data and alerts into clinical workflows to prevent unplanned hospitalisations and personalise therapy[1][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Entia addresses a concrete pain point—routine blood monitoring for cancer patients—by combining a home‑usable full blood count device with clinical workflows and trials experience; continued regulatory, payer and health‑system validation will determine whether it transitions from promising pilot partner to mainstream virtual‑oncology infrastructure[3][1][4].
Entia has raised $45.0M in total across 3 funding rounds.
Entia's investors include Parkwalk Advisors, Joanna Smart, Business Growth Fund, Innovate UK, Sussex Place Ventures, Zahir Kasmani.
Entia has raised $45.0M across 3 funding rounds. Most recently, it raised $21.0M Series A in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $21.0M Series A | Parkwalk Advisors, Joanna Smart | Business Growth Fund, Innovate UK, Sussex Place Ventures |
| Oct 12, 2021 | $12.0M Other Equity | Zahir Kasmani | Parkwalk Advisors, Sussex Place Ventures |
| Mar 1, 2021 | $12.0M Series A | Business Growth Fund, Parkwalk Advisors |